Affinity Asset Advisors
Affinity Asset Advisors reported 101 stocks worth $2B in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are ROIV (6.6%), Apogee Therapeutics Inc (6.5%) and SYRE (5.6%). Compared with Q1 2026, the fund opened new positions in TRAX, IDYA and ODTX, added to ROIV, INSM and PRAX, trimmed XENE, ERAS and ALKS and sold out of ASND, BBIO and WVE.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ROIV Roivant Sciences Ltd | $133M | 6.6% | 3.8M | +950K (+34%) | 7 of 8 | |
| 2 | APOGEE THERAPEUTICS INC | $131M | 6.5% | 987K | −298K (−23%) | 8 of 8 | |
| 3 |  SYRE Spyre Therapeutics Inc | $114M | 5.6% | 1.3M | No change | 8 of 8 | |
| 4 |  XENE Xenon Pharmaceuticals Inc | $96.3M | 4.8% | 1.6M | −80K (−5%) | 8 of 8 | |
| 5 |  ERAS Erasca Inc | $96.2M | 4.8% | 5.3M | −100K (−2%) | 8 of 8 | |
| 6 |  INSM Insmed Inc | $69.3M | 3.4% | 650K | +170K (+35%) | 8 of 8 | |
| 7 |  PRAX Praxis Precision Medicines I | $61.9M | 3.1% | 185K | +15K (+9%) | 3 of 8 | |
| 8 |  ALKS Alkermes PLC | $58.9M | 2.9% | 1.1M | −225K (−17%) | 8 of 8 | |
| 9 |  ORKA Oruka Therapeutics Inc | $56.2M | 2.8% | 590K | +90K (+18%) | 8 of 8 | |
| 10 |  ANAB Anaptysbio Inc | $55.8M | 2.8% | 826K | −114K (−12%) | 3 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CENTESSA PHARMACEUTICALS PLC | $55.6M | 1.4M |
ARCELLX INC | $41.7M | 363K |
TERNS PHARMACEUTICALS INC | $29.7M | 563K |
 ASND Ascendis Pharma A/s | $21.7M | 95K |
 BBIO Bridgebio Pharma Inc | $11.1M | 150K |
🔒 Free account: see all 9.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 MRNA Moderna Inc | Put | $35M | 500K | +500,000 |
MRNA Moderna Inc | Call | $33.3M | 475K | −325,000 |
 ARKG ARK Genomic Revolution | Call | $31.5M | 750K | +750,000 |
 LLY Eli Lilly & Co | Call | $24M | 20K | +20,000 |
 OMER Omeros Corp | Put | $13.4M | 1.4M | +1,411,300 |
🔒 Free account: see all 9.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Affinity Asset Advisors 13F FAQ
What does Affinity Asset Advisors own?
Affinity Asset Advisors reported 101 stocks worth $2B in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are ROIV (6.6%), Apogee Therapeutics Inc (6.5%) and SYRE (5.6%). The table above lists every position in the filing (the top 10 without an account).
What did Affinity Asset Advisors buy and sell in Q2 2026?
Compared with Q1 2026: 18 new positions, 32 added to, 28 trimmed and 9 sold out. New positions include TRAX, IDYA and ODTX. It sold all of ASND, BBIO and WVE.
When will Affinity Asset Advisors file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Affinity Asset Advisors's portfolio worth?
The Q2 2026 filing reports $2B in US stocks ($2.2B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.